Diabetic Retinopathy (DR)
Program: SURYA-101
SURYA-101 explores an investigational lipid-mediator approach for diabetic retinopathy. The program is currently in preclinical development and is being studied for its potential role in supporting retinal health.
Important Medical Notice
If you experience sudden vision changes, flashes, floaters, or vision loss, seek immediate medical care. This is a medical emergency.
Understanding Diabetic Retinopathy
Diabetic retinopathy (DR) is a serious complication of diabetes that affects the blood vessels in the retina—the light-sensitive tissue at the back of the eye. Over time, high blood sugar levels can damage these delicate blood vessels, leading to vision problems and, in severe cases, blindness.
Increased vascular permeability: Blood vessels become 'leaky,' allowing fluid and proteins to seep into the retina
Breakdown of the blood-retinal barrier: The protective barrier that normally keeps harmful substances out of the retina is compromised
Cell damage: Retinal neurons, endothelial cells, and pericytes (cells that support blood vessels) can undergo apoptosis (programmed cell death)
Elevated VEGF and IL-6: These signaling molecules promote abnormal blood vessel growth and inflammation
Inflammation: Chronic inflammation contributes to progressive damage
Neovascularization and hemorrhage: Abnormal new blood vessels may form and bleed, potentially leading to vision loss or retinal detachment
What is SURYA-101?
SURYA-101 is an investigational lipid mediator-based approach being developed for diabetic retinopathy. It represents a different strategy from current anti-VEGF injection therapies.
Program Summary A
SURYA-101 is described as a mixture of LXA4 (Lipoxin A4), NPD1 (Neuroprotectin D1), and RSVs (Resolvins) in a specific ratio. This combination is intended to be anti-angiogenic (inhibit abnormal blood vessel growth), cytoprotective (protect cells), anti-inflammatory, and to enhance BDNF (brain-derived neurotrophic factor) while inhibiting VEGF production.
Program Summary B
The approach centers on LXA4/AA (Lipoxin A4 derived from arachidonic acid), a low molecular weight lipid concept. Research indicates that LXA4 may block NFkB, VEGF, angiopoietin-2, and IL-6. Studies suggest that LXA4, BDNF, AA, and DHA levels are low in diabetic retinopathy patients.
About these summaries
Different program materials describe the composition in different ways. We can clarify details under NDA or upon request.
How it may work (investigational)
Proposed mechanisms of action
VEGF Signaling Reduction
SURYA-101 aims to inhibit VEGF production (not just neutralize VEGF like current therapies), potentially addressing the underlying cause of abnormal blood vessel growth.
Anti-inflammatory Pathways
The approach targets inflammatory signaling pathways including NFkB and IL-6, which contribute to progressive retinal damage in diabetic retinopathy.
Cytoprotection & Neuroprotection
SURYA-101 is intended to support BDNF levels and provide cytoprotective effects to help preserve retinal neurons and other cells.
Potential Convenience Goals
Development intent includes potentially fewer injections than current anti-VEGF therapies, with possible eye-drop formulation exploration.
Information presented represents historical observations and preclinical research. Results may not be generalizable and do not predict future clinical outcomes.
How this differs from current therapy
Category comparison (not a claim of superiority)
Current standard treatments for diabetic retinopathy include anti-VEGF monoclonal antibody injections (such as ranibizumab, aflibercept, and bevacizumab). These treatments work by neutralizing VEGF after it is produced, requiring repeated injections into the eye.
| Aspect | Current Anti-VEGF Injections | SURYA-101 (Investigational Intent) |
|---|---|---|
| Mechanism | Neutralizes VEGF after production | Aims to inhibit VEGF production |
| Administration | Intravitreal injections | Potential for eye-drop development (intent) |
| Frequency | Multiple injections over time | Potentially fewer treatments (intent) |
| Additional targets | VEGF focused | Multiple pathways (VEGF, NFκB, IL-6, BDNF) |
| Status | FDA approved, widely used | Investigational, preclinical |
This comparison represents development intent and goals, not proven claims. SURYA-101 has not been tested in clinical trials.
Development Status & Roadmap
Current status and planning estimates
Patent filed
ReportedPreclinical toxicology studies
In progressGLP studies
PlannedGMP manufacturing
PlannedIND submission
2–3 years (planning estimate)Funding estimate: Approximately $1M investment needed (planning estimate)
FAQs for Patients & Caregivers
Common questions about our diabetic retinopathy program
No. SURYA-101 is investigational and has not been approved by the FDA or any regulatory authority for clinical use. It is currently in preclinical development.
No. SURYA-101 is not currently available as a treatment option. It has not entered clinical trials. We encourage patients to discuss all available treatment options with their ophthalmologist or retina specialist.
VEGF (Vascular Endothelial Growth Factor) is a protein that tells your body to grow new blood vessels. In diabetic retinopathy, too much VEGF causes abnormal blood vessels to grow in the eye, which can leak and cause vision problems.
IL-6 (Interleukin-6) is a signaling molecule involved in inflammation. In diabetic retinopathy, elevated IL-6 contributes to ongoing inflammation and damage in the retina
BDNF (Brain-Derived Neurotrophic Factor) is a protein that helps protect and support nerve cells, including those in the retina. Research suggests BDNF levels may be low in diabetic retinopathy, and supporting BDNF could help protect retinal neurons.
Known: The scientific rationale for lipid mediator approaches based on published research; patent has been filed; preclinical studies are in progress. Unknown: Clinical safety and efficacy in humans; optimal dosing and formulation; whether development goals (fewer injections, eye drops) are achievable.
Laser treatment (photocoagulation) is another established treatment for diabetic retinopathy that works by sealing leaky blood vessels. Anti-VEGF injections have become more common for many patients. SURYA-101 represents a different investigational approach that has not been compared to any existing treatments.
The program is focused on completing preclinical toxicology studies, followed by GLP and GMP activities. The planning estimate is 2-3 years to IND submission, though timelines may change based on study results and funding.
Research has shown that certain lipid mediators like LXA4 play important roles in resolving inflammation. In diabetes, levels of beneficial lipids like LXA4, AA, and DHA may be reduced. The rationale for SURYA-101 is to potentially restore these protective pathways
You can reach us through the contact form on this website or by emailing undurti@gmail.com. We respond to all inquiries, though detailed scientific discussions may require appropriate confidentiality agreements.
Important Notice: SURYA-101 is investigational and not approved by the FDA or any regulatory authority. It is not available as an approved treatment.
Urgent symptoms: If you experience sudden vision changes, flashes, floaters, or vision loss, seek immediate medical care. This is a medical emergency.
Want to learn more?
Request our information deck or connect with our team to discuss the diabetic retinopathy program.